Triferic’s ESA-Reduction Claim Draws FDA Skepticism Ahead Of ODAC Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Rockwell’s iron replacement therapy could be hindered by absence of ESA-reduction claim even if drug makes it through FDA with more limited indication; agency will have to address its own discrepancies in briefing document data at the Nov. 6 Oncologic Drugs Advisory Committee.
You may also be interested in...
Rockwell Sees Opportunity For Triferic In Cost-Sensitive CKD Market
Rockwell Medical has filed an NDA for the iron replacement therapy, which will be positioned as an alternative to I.V. iron during dialysis and could limit the need for erythropoietin-stimulating agents.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.